Online inquiry

IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15238MR)

This product GTTS-WQ15238MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15238MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2704MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ2184MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ15280MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ7526MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ5216MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ210MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ2716MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ6202MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CP-870893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW